Moderna (MRNA, $62) was one of top quarterly gainers, jumping +106.32% to $62 per share. Tickeron A.I.dvisor analyzed 380 stocks in the Biotechnology Industry over the last three months, and discovered that 357 of them (94.07%) charted an Uptrend while 23 of them (5.93%) trended down. Tickeron A.I.dvisor found 135 similar cases when MRNA's price jumped over 15% within three months. In 84 out of those 135 cases, MRNA's price went up during the following month. Based on these historical data, Tickeron A.I. thinks the odds of an Uptrend continuation for MRNA are 62%.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.